Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia *Includes one patient who completed the study in remission, with RFS of 59.7 months (4.97 years).**One patient was censored after 43 days (1.4 months) because of withdrawal of consent.***Patients could have both rearrangements and translocations.HSCT: hematopoietic stem cell transplantation; CR1: first hematologic complete remission; CR2+: second or